Shares of Fresenius Medical Care AG (NYSE:FMS) gapped up prior to trading on Monday . The stock had previously closed at $43.46, but opened at $43.66. Fresenius Medical Care AG shares last traded at $44.04, with a volume of 59,802 shares trading hands.

Several analysts recently issued reports on FMS shares. Jefferies Group raised shares of Fresenius Medical Care AG from an “underperform” rating to a “hold” rating in a research report on Friday. Sanford C. Bernstein started coverage on shares of Fresenius Medical Care AG in a research report on Monday, April 11th. They issued an “outperform” rating for the company. Royal Bank Of Canada reissued a “hold” rating on shares of Fresenius Medical Care AG in a research report on Tuesday, May 24th. Zacks Investment Research raised shares of Fresenius Medical Care AG from a “sell” rating to a “hold” rating in a research report on Wednesday, May 4th. Finally, DZ Bank AG reissued a “sell” rating on shares of Fresenius Medical Care AG in a research report on Tuesday, May 10th. Two analysts have rated the stock with a sell rating, six have given a hold rating and six have issued a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus price target of $42.50.

The company has a 50 day moving average price of $42.61 and a 200-day moving average price of $42.74. The firm has a market cap of $26.81 billion and a P/E ratio of 25.55.

Fresenius Medical Care AG (NYSE:FMS) last announced its earnings results on Tuesday, May 3rd. The company reported $0.75 EPS for the quarter, beating analysts’ consensus estimates of $0.42 by $0.33. During the same quarter in the prior year, the company earned $0.69 EPS. The business had revenue of $4.21 billion for the quarter, compared to the consensus estimate of $4.25 billion. Fresenius Medical Care AG’s revenue was up 6.2% compared to the same quarter last year. On average, equities analysts predict that Fresenius Medical Care AG will post $2.03 earnings per share for the current fiscal year.

Other institutional investors have made changes to their positions in the company. Morgan Stanley increased its position in shares of Fresenius Medical Care AG by 20.5% in the fourth quarter. Morgan Stanley now owns 685,338 shares of the company’s stock worth $28,675,000 after buying an additional 116,653 shares in the last quarter. WBI Investments Inc. acquired a new position in shares of Fresenius Medical Care AG during the fourth quarter worth approximately $2,249,000. Bank of Montreal Can increased its position in shares of Fresenius Medical Care AG by 60.0% in the fourth quarter. Bank of Montreal Can now owns 56,700 shares of the company’s stock worth $2,373,000 after buying an additional 21,264 shares in the last quarter. Commerzbank Aktiengesellschaft FI increased its position in shares of Fresenius Medical Care AG by 46.1% in the fourth quarter. Commerzbank Aktiengesellschaft FI now owns 38,351 shares of the company’s stock worth $1,605,000 after buying an additional 12,105 shares in the last quarter. Finally, US Bancorp DE increased its position in shares of Fresenius Medical Care AG by 4.0% in the fourth quarter. US Bancorp DE now owns 274,935 shares of the company’s stock worth $11,503,000 after buying an additional 10,479 shares in the last quarter.

Fresenius Medical Care AG & Co KGaA (FMC AG & CO. KGAA) is a kidney dialysis company. The Company provides dialysis care and related services to persons suffering from end stage renal disease (ESRD), as well as other healthcare services. The Company operates through four segments: North America, Europe, Middle East, Africa (EMEA), Asia-Pacific and Latin America.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.